Mercer Global Advisors
RLAY icon

Mercer Global Advisors’s Relay Therapeutics RLAY Stock Holding History

Mercer Global Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$336K Buy
17,981
+1,560
+10% +$22.6K ﹤0.01% 2679
2026
Q1 		$163K Buy
16,421
+3,583
+28% +$32.1K ﹤0.01% 2901
2025
Q4 		$109K Sell
12,838
-217
-2% -$1.55K ﹤0.01% 2703
2025
Q3 		$68.1K Buy
+13,055
New +$49.8K ﹤0.01% 2569

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Mercer Global Advisors's RLAY Position: Q2 2026 in Review

Mercer Global Advisors increased its Relay Therapeutics (RLAY) stake by 9.5% in Q2 2026, buying an estimated $22.6K and bringing the position to 17,981 shares worth $336K. The position accounts for ﹤0.01% of the portfolio, ranked #2679.

Mercer Global Advisors first reported a position in RLAY in Q3 2025 and has held it in 4 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Mercer Global Advisors held 17,981 shares of Relay Therapeutics worth $336K as of Q2 2026.
  • Mercer Global Advisors bought 1,560 Relay Therapeutics shares in Q2 2026, an estimated $22.6K.
  • Relay Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #2679 holding.
  • Mercer Global Advisors first reported a position in Relay Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.